Kaltsas G A, Powles T B, Evanson J, Plowman P N, Drinkwater J E, Jenkins P J, Monson J P, Besser G M, Grossman A B
Department of Endocrinology, St. Bartholomew's Hospital, London, United Kingdom.
J Clin Endocrinol Metab. 2000 Apr;85(4):1370-6. doi: 10.1210/jcem.85.4.6501.
Langerhans cell histiocytosis (LCH) is a rare disorder in which granulomatous deposits occur at multiple sites within the body, but which often involves the hypothalamo-pituitary axis (HPA). Although diabetes insipidus (DI) is a well recognized complication, the frequency of anterior pituitary and other nonendocrine hypothalamic (NEH) involvement has not been well defined, particularly in adult patients with the disease. We have evaluated the frequency and progression of LCH-related anterior pituitary and other NEH dysfunction and their responses to treatment in 12 adult patients with histologically proven LCH and DI. They were followed up for a median of 11.5 yr (range, 3-28 yr) after the diagnosis of DI was made. Study evaluations comprised clinical (including formal psychometric assessment where appropriate), basal and dynamic pituitary function tests, and radiology with computed tomography and/or magnetic resonance imaging scanning. Eleven patients received systemic treatment, and 5 patients received external beam radiotherapy confined to the HPA. The median age at diagnosis of DI was 34 yr (range, 2-47 yr); DI was the presenting symptom in four patients, whereas the remaining eight each developed DI 1-20 yr (median, 2 yr) after the diagnosis of LCH. Eight patients developed one or more anterior pituitary hormonal deficiencies at a median of 4.5 yr (range, 2-22 yr) after the diagnosis of DI: GH deficiency developed in eight patients (median, 2 yr; range, 2-22 yr), FSH-LH deficiency in 7 patients (median, 7 yr; range, 2-22 yr), and TSH and ACTH deficiency in five patients (median, 10 yr; range, 3-16 and 3-19 yr), respectively; five patients developed panhypopituitarism. In addition, seven patients with anterior pituitary dysfunction also developed symptoms of other NEH dysfunctions at a median of 10 yr (range, 1-23 yr): five morbid obesity (body mass index, >35), five short term memory deficits, four sleeping disorders, two disorders of thermoregulation, and one adipsia. All patients developed disease outside of the hypothalamus during the course of the study, and no fluctuation of disease activity in the HPA region was noted. Radiological examination of the HPA was abnormal in each of the eight patients with anterior pituitary involvement and in the seven patients with NEH dysfunction (one or more abnormalities): seven had thickening of the infundibulum, and one had hypothalamic and thalamic signal changes. All patients who had a magnetic resonance imaging scan had absence of the bright spot of the posterior pituitary on the T1-weighted sequences, and in four patients with DI and normal anterior pituitary function this was the only abnormality. The five patients who received radiotherapy to the HPA achieved a partial or complete radiological response, and there was no evidence of tumor progression in this region. No form of therapy, including chemotherapy, improved any established hormonal deficiencies or symptoms of NEH. In summary, in our adult patients with hypothalamic LCH and DI, anterior pituitary hormonal deficiencies developed in 8 of 12 patients; these occurred over the course of 20 yr. They were frequently accompanied by structural changes of the HPA, although these were often subtle in nature. In addition, symptoms of NEH dysfunction developed in up to 90% of such patients and complicated management. Radiotherapy may be useful in achieving local control of tumor, but established anterior, posterior pituitary, and other NEH dysfunctions do not improve in response to current treatment protocols. Patients with LCH and DI, particularly those with multisystem disease and a structural lesion on radiology, should undergo regular and prolonged endocrine assessment to establish anterior pituitary deficiency and provide appropriate hormonal replacement.
朗格汉斯细胞组织细胞增多症(LCH)是一种罕见疾病,其中肉芽肿性沉积物出现在身体多个部位,但常累及下丘脑 - 垂体轴(HPA)。虽然尿崩症(DI)是一种公认的并发症,但垂体前叶和其他非内分泌性下丘脑(NEH)受累的频率尚未明确界定,尤其是在成年患者中。我们评估了12例经组织学证实患有LCH和DI的成年患者中LCH相关的垂体前叶和其他NEH功能障碍的频率、进展及其对治疗的反应。在确诊DI后,对他们进行了中位时间为11.5年(范围3 - 28年)的随访。研究评估包括临床评估(酌情包括正式的心理测量评估)、基础和动态垂体功能测试以及计算机断层扫描和/或磁共振成像扫描的放射学检查。11例患者接受了全身治疗,5例患者接受了局限于HPA的外照射放疗。DI诊断时的中位年龄为34岁(范围2 - 47岁);4例患者以DI为首发症状,其余8例在LCH诊断后1 - 20年(中位时间2年)出现DI。8例患者在DI诊断后中位时间4.5年(范围2 - 22年)出现一种或多种垂体前叶激素缺乏:8例患者出现生长激素缺乏(中位时间2年;范围2 - 22年),7例患者出现促卵泡激素 - 促黄体生成素缺乏(中位时间7年;范围2 - 22年),5例患者分别出现促甲状腺激素和促肾上腺皮质激素缺乏(中位时间10年;范围3 - 16年和3 - 19年);5例患者出现全垂体功能减退。此外,7例垂体前叶功能障碍患者在中位时间10年(范围1 - 23年)也出现了其他NEH功能障碍的症状:5例病态肥胖(体重指数>35),5例短期记忆缺陷,4例睡眠障碍,2例体温调节障碍,1例烦渴。在研究过程中,所有患者下丘脑外均出现疾病,且未观察到HPA区域疾病活动的波动。8例垂体前叶受累患者和7例NEH功能障碍患者(一种或多种异常)的HPA放射学检查均异常:7例漏斗部增厚,1例下丘脑和丘脑信号改变。所有接受磁共振成像扫描的患者在T1加权序列上均无垂体后叶亮点,4例DI且垂体前叶功能正常的患者中,这是唯一的异常。5例接受HPA放疗的患者获得了部分或完全放射学缓解,该区域无肿瘤进展的证据。包括化疗在内的任何治疗方式均未改善已存在的激素缺乏或NEH症状。总之,在我们患有下丘脑LCH和DI的成年患者中,12例患者中有8例出现垂体前叶激素缺乏;这些情况在20年期间发生。它们常伴有HPA的结构改变,尽管这些改变通常性质较为细微。此外,高达90%的此类患者出现NEH功能障碍症状,使管理复杂化。放疗可能有助于实现肿瘤的局部控制,但已存在的垂体前叶、垂体后叶和其他NEH功能障碍对当前治疗方案无反应。患有LCH和DI的患者,尤其是那些有多系统疾病且放射学上有结构性病变的患者,应接受定期和长期的内分泌评估,以确定垂体前叶功能减退并提供适当的激素替代治疗。